Back to Search
Start Over
Osivax announces first participant vaccinated in phase 2a clinical booster trial of influenza vaccine candidate OVX836
- Source :
- PharmaBiz. November 16, 2024
- Publication Year :
- 2024
-
Abstract
- Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, announced that the first participant has been vaccinated in a phase 2a clinical trial (NCT06582277) [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PharmaBiz
- Publication Type :
- Periodical
- Accession number :
- edsgcl.816471558